Evidence map›Paper›PMID 19826573›Full record

ArticleReviews in obstetrics & gynecology2009

Uses of misoprostol in obstetrics and gynecology.

Rebecca Allen, Barbara M O'Brien

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Reviews in obstetrics & gynecology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01762319 naunknown statusnot on this mapstarted 2012, after this paper: background citation

Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial

TypeinterventionalSponsorMahidol UniversityRan2012 to 2013Enrolled52ConditionsAbnormal Uterine Bleeding Unrelated to Menstrual CycleArmsMisoprostol, Vitamin B6
NCT05341817 phase4recruitingnot on this mapstarted 2022, after this paper: background citation

The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy: a Randomized, Non-inferiority Trial

TypeinterventionalSponsorKK Women's and Children's HospitalRan2022 to 2025Enrolled144ConditionsAbortion in First TrimesterArmsLetrozole, Mifepristone
NCT06207539 early_phase1completednot on this mapstarted 2022, after this paper: background citation

Use Of Hyoscine as An Adjuvant Treatment on Shortening the Time of Abortion Induction in Second Trimester: Randomized Controlled Clinical Trial

TypeinterventionalSponsorAin Shams Maternity HospitalRan2022 to 2023Enrolled40ConditionsAbortion, Second TrimesterArmshyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company, misoprostol under the generic name of misotac tablets
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Misoprostol for intrauterine device placement.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Methods of induction of labour: a network meta-analysis.The Cochrane database of systematic reviews · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. The hormonal control of parturition.Physiological reviews · 2024
    Review
  11. Article
  12. Review
  13. Updating an Overview of Teratology.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  14. Article
  15. Article
  16. Misoprostol use in obstetrics.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2023
    Article
  17. Misoprostol Administration Before Hysteroscopy Procedures - A Retrospective Analysis.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022
    Observational
  18. Review
  19. In vivo Raman spectroscopy monitors cervical change during labor.American journal of obstetrics and gynecology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rebecca AllenDepartment of Obstetrics and Gynecology, Women and Infants' Hospital and Warren Alpert Medical School of Brown University Providence, RI.
Barbara M O'Brien
Brown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Misoprostol is a synthetic prostaglandin E(1) analogue that is used off-label for a variety of indications in the practice of obstetrics and gynecology, including medication abortion, medical management of miscarriage, induction of labor, cervical ripening before surgical procedures, and the treatment of postpartum hemorrhage. Due to its wide-ranging applications in reproductive health, misoprostol is on the World Health Organization Model List of Essential Medicines. This article briefly reviews the varied uses of misoprostol in obstetrics and gynecology.

Indexed as

Cervical ripeningHysteroscopyInduced abortionInduction of laborMisoprostolPostpartum hemorrhage

Identifiers

PMID19826573
PMCPMC2760893
OpenAlexW26175460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.